NRIX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NRIX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Nurix Therapeutics's Cost of Goods Sold for the three months ended in Feb. 2024 was $0.00 Mil. Its Revenue for the three months ended in Feb. 2024 was $16.59 Mil.
Nurix Therapeutics's COGS to Revenue for the three months ended in Feb. 2024 was 0.00.
Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Nurix Therapeutics's Gross Margin % for the three months ended in Feb. 2024 was N/A%.
The historical data trend for Nurix Therapeutics's COGS-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nurix Therapeutics Annual Data | |||||||||||||||
Trend | Nov18 | Nov19 | Nov20 | Nov21 | Nov22 | Nov23 | |||||||||
COGS-to-Revenue | Get a 7-Day Free Trial | - | - | - | - | - |
Nurix Therapeutics Quarterly Data | ||||||||||||||||||||
May19 | Aug19 | Nov19 | Feb20 | May20 | Aug20 | Nov20 | Feb21 | May21 | Aug21 | Nov21 | Feb22 | May22 | Aug22 | Nov22 | Feb23 | May23 | Aug23 | Nov23 | Feb24 | |
COGS-to-Revenue | Get a 7-Day Free Trial | - | - | - | - | - |
Nurix Therapeutics's COGS to Revenue for the fiscal year that ended in Nov. 2023 is calculated as
COGS to Revenue | = | Cost of Goods Sold | / | Revenue |
= | 0 | / | 76.987 | |
= | 0.00 |
Nurix Therapeutics's COGS to Revenue for the quarter that ended in Feb. 2024 is calculated as
COGS to Revenue | = | Cost of Goods Sold | / | Revenue |
= | 0 | / | 16.585 | |
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nurix Therapeutics (NAS:NRIX) COGS-to-Revenue Explanation
Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.
Nurix Therapeutics's Gross Margin % for the three months ended in Feb. 2024 is calculated as:
Gross Margin % | = | 1 | - | COGS to Revenue |
= | 1 | - | Cost of Goods Sold / Revenue | |
= | 1 | - | 0 / 16.585 | |
= | N/A % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.
Thank you for viewing the detailed overview of Nurix Therapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Houte Hans Van | officer: Chief Financial Officer | C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158 |
Christine Ring | officer: General Counsel | C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158 |
Gwenn Hansen | officer: Chief Scientific Officer | C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158 |
Stefani Wolff | officer: EVP and COO | C/O PRINCIPIA BIOPHARMA INC., 400 EAST JAMIE COURT, SUITE 302, SOUTH SAN FRANCISCO CA 94080 |
Edward C Saltzman | director | C/O NURIX THERAPEUTICS, 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158 |
Paul M Silva | director | C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST, CAMBRIDGE MA 02139 |
Judith A Reinsdorf | director | C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974 |
Pierre Beaurang | officer: Chief Business Officer | C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158 |
Clay B Siegall | director | 21823 30TH DR SE, BOTHELL WA 98021 |
Ponoi Capital, Lp | 10 percent owner | 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Ponoi Ii Management, Llc | 10 percent owner | 1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129 |
Ponoi Capital Ii, Lp | 10 percent owner | 1700 OWENS STREET, STE 500, SAN FRANCISCO CA 94158 |
Column Group Gp, Lp | 10 percent owner | 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Column Group L P | 10 percent owner | 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Ponoi Management, Llc | 10 percent owner | 1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129 |
From GuruFocus
By Value_Insider Value_Insider • 12-07-2022
By Marketwired • 08-31-2023
By sperokesalga sperokesalga • 06-14-2023
By Marketwired • 09-07-2023
By sperokesalga sperokesalga • 04-11-2023
By Stock market mentor Stock market mentor • 01-09-2023
By sperokesalga sperokesalga • 03-20-2023
By Ds*** Ds*** • 08-31-2022
By GuruFocus Research • 12-21-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.